酒精相关性肝病的无创检测
本文综述酒精相关性肝病(ALD)无创检测(NIT)的应用,涵盖酒精摄入生物标志物、无症状风险人群筛查及代偿期肝硬化、晚期慢性肝病、酒精相关性肝炎等的诊断与预后评估,并讨论筛查机会与挑战。
要点
- 无创酒精摄入生物标志物有助于评估近期饮酒量及饮酒模式。
- NIT可用于人群分层识别ALD风险及预测肝脏相关症状。
- NIT在酒精相关性肝炎、失代偿期肝硬化等预后评估中起重要作用。
核心结论
- NIT是检测ALD的关键工具,为早期识别和干预提供机会以减轻疾病负担。
研究设计与样本
- 综述,讨论用于早期检测和监测饮酒的各种NIT,并综合评估NIT用于筛查和预测ALD及肝脏并发症。
主要发现
- 仅小部分ALD患者在其他慢性肝病相比下于早期阶段被识别。
- NIT应用于两大临床场景:人群分层识别和预测肝脏相关症状,以及在二级或三级医疗中诊断和预后代偿期肝硬化或晚期慢性肝病。
- NIT用于评估酒精相关性肝炎、失代偿期肝硬化、代谢相关合并ALD等表现的预后,指导治疗决策并预测结局。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Alcohol consumption is a global phenomenon and a major contributor to alcohol-associated liver disease (ALD). Detecting individuals at risk of ALD has been challenging, with only a small fraction of patients being identified at early stages compared to other chronic liver diseases. In response to this challenge, non-invasive tests (NITs) have become essential tools for the detection of ALD, offering opportunities for early identification and intervention to mitigate the disease burden. Noninvasive alcohol consumption biomarkers are crucial in estimating individuals' recent alcohol intake, providing valuable insights into their drinking patterns. Various NITs have been investigated for the initial screening of asymptomatic individuals at risk of ALD, as well as for identifying specific stages of the disease. These NITs are applied in 2 main clinical scenarios: population-based stratification for identifying and predicting liver-related symptoms and diagnosing and prognosticating compensated cirrhosis or advanced chronic liver disease in secondary or tertiary care settings. Moreover, NITs play a significant role in the prognostic assessment of patients with various manifestations of ALD, including alcohol-associated hepatitis (AH), decompensated cirrhosis, and metabolic-associated and ALD. These tests guide appropriate treatment decisions and predict outcomes. In this review, various NITs for the early detection and monitoring of alcohol consumption were discussed. Additionally, the evaluation of NITs for screening and predicting ALD and liver complications was addressed comprehensively. Future perspectives of NITs for ALD were explored, alongside a thorough discussion of the opportunities and challenges associated with NITs for ALD screening.
引用
- Israelsen M, Rungratanawanich W, Thiele M, et al. Non-invasive tests for alcohol-associated liver disease. Hepatology. 2024. PMID: 38607723. doi:10.1097/HEP.0000000000000885
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。